Lung injury and respiratory failure is a major causes of death after HCT.
Although the BMT-CTN has a focused agenda on GVHD, reduction of lung toxicities will be important to improve outcomes.
NHLBI should encourage researched from the... more »
Can biomarkers make all the use of new predictive biomarkers enable earlier and more effective treatment of acute GVHD? Can biomarkers accurately guide reduction in therapy for patients who will respond to standard steroid treatment? Can biomarkers enable earlier and thus more effective therapy for high risk GVHD? Can new biomarkers (proteomic, genomic or a combination) also predict patients who are risk of relapse?
Vaccination responses are poor early after hematopoietic cell transplantation and in the context of cytotoxic chemotherapy. To design effective vaccination strategies it is critical to understand the immune correlates of protection. There is a need to study strategies to study and improve vaccine efficacy in this growing population of immunosuppressed individuals that is increasingly of advanced age.